Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline

This is the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism, published in The Journal of Clinical Endocrinology and Metabolism. The document is the framework most US endocrinology and internal-medicine practice operates within, replacing the 2010 guideline and providing the diagnostic logic, candidate-selection criteria, monitoring conventions, and contraindication list that define mainstream hypogonadism care. It is a Tier 2 source in the corpus's framework — a peer-reviewed consensus guideline grounded in systematic-review evidence ratings, not a primary trial — but its load-bearing role in clinical practice and in the andropause-and-peptides conversation makes it a central reference.

The diagnostic recommendation is the most editorially consequential. The task force recommends "making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone concentrations." Biochemistry alone is insufficient; symptoms alone are insufficient. Practical workup requires fasting morning total testosterone measured by an accurate assay (mass spectrometry or a CDC-Hormone-Standardization-Program-certified immunoassay), with confirmation on a separate morning sample before any treatment decision. Free testosterone is added when total testosterone is in the borderline range or when sex-hormone-binding globulin is suspected of being altered (obesity, diabetes, thyroid disease, aging). The harmonized reference range from the four CDC-standardized labs places the 2.5th–97.5th percentile for healthy non-obese young men at approximately 264–916 ng/dL — the empirical basis for the threshold below which the guideline applies, with the older "300 ng/dL" clinical cutoff approximating the assay's lower bound.

The treatment recommendation is correspondingly conservative. Testosterone therapy is recommended for men meeting both diagnostic criteria, with the aim of inducing and maintaining secondary sex characteristics and correcting symptoms of deficiency. Testosterone therapy is recommended against in men planning fertility in the near term, men with breast or prostate cancer, men with hematocrit above the upper-normal limit, men with untreated severe obstructive sleep apnea, men with recent (within six months) myocardial infarction or stroke, and men with thrombophilia. The monitoring framework calls for symptom assessment, hematocrit measurement, prostate-specific antigen, and cardiovascular and venous-thromboembolism risk evaluation during the first year of therapy, with longer-interval follow-up thereafter.

Where the guideline matters for the peptide conversation: the diagnostic stringency closes off the broad "low T" framing common in commercial men's-health channels. The contraindication list — fertility, prostate cancer, hematocrit elevation, untreated sleep apnea, recent cardiovascular events — drives the patient population for whom HPG-axis-preserving alternatives (hCG, SERMs, gonadorelin) are the structurally appropriate first-line approach rather than exogenous testosterone. The fertility carve-out specifically is the largest single source of demand for hCG monotherapy and SERM-based pathways characterized in Coviello et al. 2005 and Habous et al. 2018. See andropause-and-peptides for the broader framing and the TRT discontinuation playbook for the recovery-pathway treatment of men exiting exogenous therapy.